Navigation Links
A new light on tumor immunotherapy for gastric cancer
Date:12/23/2008

Dendritic cells (DCs) are professional antigen presenting cells (APCs) that both initiate and modulate the immune response. DCs are cells in the pathway of antigen capture and presentation to T cells, with the unique ability to directly prime nave CD4+ and CD8+ T cells. Gastric cancer is one of the most common cancers. Although gastric cancer therapy has made great progress, it is still difficult to treat advanced gastric cancer, as it has spread to the lymph glands and metastasized. Currently, tumor immunotherapy for gastric cancer has potential. DCs are believed to be essential for stimulating tumor-specific cytotoxic T lymphocyte (CTL) and inducing the protective and therapeutic anti-tumor immunity.

A research team led by Dr. Liang Wang from China investigated whether bone marrow-derived DCs (BM-DCs) pulsed with tumor lysates induce immunity against gastric cancer. Their results will be published on December 14, 2008 in the World Journal of Gastroenterology.

In this study, c-kit+ hematopoietic progenitor cells were magnetically isolated with a MiniMACS separator from BALB/c mice bone marrow cells. These cells were cultured with cytokines GM-CSF, IL-4, and TNF-alpha to induce their maturation. They were analysed by morphological observation, phenotype analysis, and mixed lymphocyte reaction (MLR). BM-DCs were pulsed with tumor cell lysate obtained by rapid freezing and thawing at a 1:3 DC:tumor cell ratio. Finally, CTL activity and interferon-gamma secretion was evaluated ex vivo

They found that c-kit+ hematopoietic progenitor cells from mice bone marrow cells cultured with cytokines for 8 d showed the character of typical mature DCs. However, immature DCs cultured with cytokines for 5 d did not have typical DCs phenotypic markers and could not stimulate allogeneic T cells. Ex vivo primed T cells with SGC-7901 tumor cell lysate-pulsed (TP) DCs were able to induce effective CTL activity against SGC-7901 tumor cells (E:T = 100:1, 69.55% 6.05% specific lysis), but not B16 tumor cells, and produced higher levels of IFN-gamma when stimulated with SGC-7901 tumor cells but not when stimulated with B16 tumor cells (1575.31 60.25 pg/mL in SGC-7901 group vs 164.11 18.52 pg/mL in B16 group, P < 0.01). These results indicated that BM-derived DCs pulsed with tumor lysates can induce anti-tumor immunity specific to gastric cancer ex vivo.


'/>"/>

Contact: Lai-Fu Li
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Guardian Life Flight, Air Ambulance Service Provider, Announces Addition of Sam Kini, M.D. To Its Team
2. Annual Congress European Association of Urology: highlights in Stockholm
3. Festival of Lights Holiday Celebration
4. Easter Seals Study Sheds New Light on Parents Life-Long Fears, Anxieties and Critical Supports Needed to Raise a Child With Autism
5. Electronic Sports Launches Dogfight Fitness Flight Simulator: The Next Generation of Exergaming
6. U.S. Supreme Court Ruling Allowing Light Cigarette Lawsuits Is Victory for Consumers and Health
7. New Report to Highlight Need for Public Health Insurance Plan Outlined in Obamas Proposals
8. Narrow-band imaging comparable to white light colonoscopy in differentiating colorectal polyps
9. Light shines for potential early cancer diagnosis technique
10. Sinobiopharma Reports Highlights of Third Quarter Results for Its Operating Subsidiary, Dong Ying China
11. Experts Highlight New Tool as a Timely Addition to Asthma Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , the leading provider ... the clinical trials market. Similar to its approach in demonstrating positive outcomes in the ... marketplace by proving the value of eVisits to support virtual studies. , ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... in Cincinnati, OH for leading-edge care, whether or not they have a referral. ... the BIOLASE WaterLase® iPlus™ laser, she targets bacteria and damaged tissue without affecting ...
(Date:6/20/2017)... JEFFERSON HILLS, PA (PRWEB) , ... June 20, ... ... now available at Allegheny Health Network’s (AHN) Jefferson Hospital is providing physicians with ... 1.5T, 48-channel scanner provides higher-resolution images than traditional MRIs, enabling doctors to get ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... SweetLeaf® Stevia Sweetener, Michael P. May, Ph.D., recently accepted the distinguished Sun Corridor ... Program selected Wisdom Natural Brands (WNB), and 16 other businesses from Pima, Pinal, ...
(Date:6/20/2017)... ... 20, 2017 , ... BrightStar Care Centerville/South Dayton, a home ... Joint Commission, which accredits and certifies nearly 21,000 healthcare organizations and programs in ... symbol of quality that reflects an organization’s commitment to meeting certain performance standards. ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
(Date:5/30/2017)... May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... Global Healthcare Conference on Tuesday, June 13, 2017, in ... , Hill-Rom,s president and chief executive officer, is scheduled to ... audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . A ... the live event through September 13, 2017. ...
Breaking Medicine Technology: